To demonstrate the superiority of terutroban over a marketed drug (antithrombotic agent) in reducing the number of cerebrovascular and cardiovascular events in patients with cerebrovascular diseases.
- Warfarin (Coumadin®)Drug
Intervention Desc: Anticoagulant (Vitamin K antagonist)
- S 18886 (Terutroban)Drug
Intervention Desc: thromboxane receptor antagonist
Randomized, double-blind, parallel-group study
Patients 55 and greater post-stroke will be randomized to either S 18886 or an antithrombotic agent.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Cerebrovascular and cardiovascular events|